A requirement for FcγR in antibody-mediated bacterial toxin neutralization
Open Access
- 4 October 2010
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 207 (11) , 2395-2405
- https://doi.org/10.1084/jem.20100995
Abstract
One important function of humoral immunity is toxin neutralization. The current view posits that neutralization results from antibody-mediated interference with the binding of toxins to their targets, a phenomenon viewed as dependent only on antibody specificity. To investigate the role of antibody constant region function in toxin neutralization, we generated IgG2a and IgG2b variants of the Bacillus anthracis protective antigen-binding IgG1 monoclonal antibody (mAb) 19D9. These antibodies express identical variable regions and display the same specificity. The efficacy of antibody-mediated neutralization was IgG2a > IgG2b > IgG1, and neutralization activity required competent Fcγ receptor (FcγR). The IgG2a mAb prevented lethal toxin cell killing and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase cleavage more efficiently than the IgG1 mAb. Passive immunization with IgG1 and IgG2a mAb protected wild-type mice, but not FcγR-deficient mice, against B. anthracis infection. These results establish that constant region isotype influences toxin neutralization efficacy of certain antibodies through a mechanism that requires engagement of FcγR. These findings highlight a new parameter for evaluating vaccine responses and the possibility of harnessing optimal FcγR interactions in the design of passive immunization strategies.Keywords
This publication has 63 references indexed in Scilit:
- Analysis of the Fc Gamma Receptor-Dependent Component of Neutralization Measured by Anthrax Toxin Neutralization AssaysClinical and Vaccine Immunology, 2009
- Identification of Linear Epitopes in Bacillus anthracis Protective Antigen Bound by Neutralizing AntibodiesJournal of Biological Chemistry, 2009
- Capsular Localization of theCryptococcus neoformansPolysaccharide Component GalactoxylomannanEukaryotic Cell, 2009
- Immunogenicity of Bacillus anthracis Protective Antigen Domains and Efficacy of Elicited Antibody Responses Depend on Host Genetic BackgroundClinical and Vaccine Immunology, 2008
- Anamnestic Protective Immunity to Bacillus anthracis Is Antibody Mediated but Independent of Complement and Fc ReceptorsInfection and Immunity, 2008
- Prophylaxis and Therapy of Inhalational Anthrax by a Novel Monoclonal Antibody to Protective Antigen That Mimics Vaccine-Induced ImmunityInfection and Immunity, 2006
- A Monoclonal Antibody to Bacillus anthracis Protective Antigen Defines a Neutralizing Epitope in Domain 1Infection and Immunity, 2006
- Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathwayThe Journal of cell biology, 2004
- Human antibodies from immunized donors are protective against anthrax toxin in vivoNature Biotechnology, 2003
- Anthrax Lethal Factor Cleaves the N-Terminus of MAPKKs and Induces Tyrosine/Threonine Phosphorylation of MAPKs in Cultured MacrophagesBiochemical and Biophysical Research Communications, 1998